del 11(q23) as a prognostic factor of iron overload in refractory anemia with ringed sideroblasts by Chauffaille, Maria de Lourdes Lopes Ferrari et al.
Maria de Lourdes Lopes Ferrari Chauffaille, José Tadeu Stéfano,
Rosana Maria Valério, Maura Romeo, Maria Madalena Rodrigues,
José Kerbauy
MEBíêAi OURN
deI 11(q23) as a prognostic factor ofiron overload in
refractory anemia with ringed sideroblasts
Disciplina de Hematologia e Hemoterapia, Escola Paulista de Medicina-UNIFESP - São Paulo, Brazil
We present the case of a patient with MOS RARS subtype with loss of part of the long arm of chromosome 11 dei 11(q23). This a
cytogenetic abnormality that occurs in 7°1o to 20°10 of RARS cases not related to poor prognosis. It seems that this deletion is a marker
of iron overload in MOS.
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INTRODUCTION.
Myelodysplastic syndrome (MDS) is acIonaIpluripotent stem cell proliferation. The termgathers together a group of disorders that show
hematological cell displasia with different leveIs óf
peripheral cytopenia, gene~ally with hypercellular bone
marrow. Defective maturation is associated with the
precursor cell proliferation.
Usually, patients are older than 50 years, MDS being
rare in childhood and adolescence, and symptoms relate
directly to cytopenia. The etiology is almost alwaysunkn9wn
(primary MDS) but can be secondary to myelotoxic drugs
like the antineoplastic ones (secondary MDS).
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FAB classification has established 5 subtypes I:
refractory anemia(RA), refractory anemia with ringed
sideroblasts (RARS), refractory anemia with excess of
blasts(RAEB), refractory anemia ~ith excess of blasts
in transformation (RAEBt) and chronic myelomonocytic
leukemia (CMML), though some clinicaI presentations
do not fit into any of them, like MD~ with marrow
fibrosis or hypocellularity.
Around 80% of the patients present karyotype
abnormalities in marrow cells, the most frequent being:
trissomy 8, loss of part of the long .arms of chromosomes
5,7,9,20 or 21, and monossomy 7.or 9.2 These
abnormalities are of independent prognostic value.
Vorhoef et al.(1991) studied karyotype prognostic
importance in MDS patients and observed differ~nt
survival times among patients with complex karyotype (7
months of survival) versus single abnormalities (21
months) versus normal karyotype (30 months).
Evolution follows the subtype. So, benign subtypes
like RA and RARS rarely evolve into acute leukemia, and
the patient r~mains with chronic anemia refractory to
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therapy. The subtypes RAEB, RAEBt and CMML are
more aggressive in that 30 to 50% of the patients evolve
into acute leukemia with mean survival of 5 to 10 months
for the first two, and 20 months for CMML.
Acquired RARS is a chronic macrocytic anemia
related to a disorder in heme biosynthesis, ineffective
erythropoiesis without reticulocytosis and mitocondrial
iron overload that leads to the presentation of more than
15 ringed sideroblasts per 100 erythroblasts. Only 10%
evolve into acute myeloid leukemia (AML). Serum iron,
ferritin and transferin saturation leveIs are high, as well as
in bone marrow, as shown by cytochemical staining.
Here, the case of a patient with RARS and chromosomal
abnormality deI 11(q23) with iron overload is presented.
Since then she has needed transfusional support (a mean
of two concentrate packs every 2-3 weeks). In September
1995 ferritin was 6,500ugll (normal= 155) and desferoxiamin
was started. WBC and platelets were maintained. Bone
marrow karyotype presented 46,XX,del11(q23) (Fig. 2).
DISCUSSION
Abnormalities involving chromosome 11 band q23
such as translocations or deletions, are frequently seen in
AML with monocytic involvement (M5 or, rarely, M4) or
in leukemias that occur in infancy, and present t(4; 11) with
biphenotypic immunological aspect (monocytic and
lymphoid). Recently, secondary AML and MOS with deI
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Figure 1 - Shows hemoglobin leveis (g%) at different follow up
times (dates). Soon after diagnosis there was a short-term
improvement. In December 93 there was a hemolysis episode.
Afterwards the patient was in need of blood transfusions.
A.R., a 62 year old white female patient, frrst carne to
our hospital in November 1992 complaining of having had
weakness for 3 months. She had been treated in another
hospital with iron and folic acid supplementation without
success. She referred the use of hair dyes and field working
from childhood until40 years old with exposure to agrotoxins.
She was in good physical condition, obese, with
pallor +++/4, liver at 1cm from right costal margin,
unpalpable spleen, Hb=5.8g%; Ht= 17%, anisocytosis+,
macrocytosis+, microcytosis+, hypocromia++ and
ovalocites+/4, WBC=3,000/mm3, 2% stick, 64%
segmented, 2% basophils, 1% eosinophils, 28%
lymphocytes and 3% monocytes. Platelets were 460,000/
mm3 with macroplatelets. HyperCellular bone marrow with
a granulocyte to eJ"ythrocyte ratio of 0.8: 1. Erythroid
hyperplasia (44%) with slight dyserythropoiesis and rare
nuclear budding; normoplastic granulocytic series (42.4%)
with 0.6% blasts aI?d some hypergranular cells; mature
lymphocytes (8.8%) and hyperplastic megakaryocytic with
displasia and micromegakaryocytes. Bone marrow iron
was abundant and there was 41 % sideroblasts, 27% of
which were ringed. Bone marrow biopsy (iliac bone) had
70% cellularity with erythroid hyperplasia and granulocytic
proliferation fitting the criteria for MOS diagnosis. Ham
test was negati ve and neutrophil alkaline phosphatase score
was 101(nl=15-75). Fetal Hb 0.6%.
The patient was followed up and presented a slight
clinicaI and hematological improvement for a short period
of time (Fig 1). Afterwards, she presented an episode of
fever, hepatomegaly and hemolysis due to infection with
hemoglobin falling to 2.5g% and an increase of indirect
bilirrubin and OHL (1.7 and 1121 respectively).
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11q in patients previously exposed to epipodophyllotoxins
have also been described.3
deI 11q has been described in different MDS subtypes,
though it is more frequent among RA and RARS. Musilova
et aI. have found 13.8% del11q in RA and 9.9% in MDS .
It seems that around 30% of RARS patients have
chromosomal abnormalities and del11q is found in 7% to
20% of these cases. Many works show different break
regions in chromosome 11, from q 14 to q23. Thus, ferritin
H chain gene located at 11q 14 would not always be
involved in these abnormalities. Mecucci et aI. (1987)
observed that deI 11q was related to bone marrow iron
overload and to an increase in ringed sideroblasts, among
13 patients with MDS retrospectively studied.
Considering that the patient received 90 red blood
cell transfusion packs and that each one contained from
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200 to 250mg of iron, resulting in an iron accumulation
equal to 22,500mg , such a high ferritin leveI is not
justified. Now, if each 1ug/L of serum ferritin is equivalent
to 8mg of stored iron, the 6,500mg/L found would mean
52,000mg of iron, ie effectively more than twice the
amount administered by transfusions:However, this could
be justified by the chromossomal abnormality that
predisposes to iron overload. It should also be recalled
that at diagnosis, the patient had bone marrow iron
overload demonstrated by Perls staining.4
The present report describes a clinically typical MDS
RARS case wi.th an unusual acquired karyotypic
abnonnality that predisposes to non random iron overload.
Future molecular studies must be done to identify its
meaning since other hematological disorders have the same
cytogenetic alteration.
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